Center-Authored Papers

Filters: Author is Advani, Anjali S  [Clear All Filters]
Journal Article
Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M et al..  2017.  Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.. The Lancet. Haematology. Abstract
Saygin C, Papadantonakis N, Cassaday RD, Liedtke M, Fischer K, Dunn T, Patel BJ, Sobecks R, Kalaycio M, Sekeres MA et al..  2017.  Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.. Leukemia & lymphoma. :1-9. Abstract
Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP et al..  2010.  Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.. British journal of haematology. 151(5):430-4. Abstract
Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M et al..  2014.  SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.. British journal of haematology. Abstract
Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR.  2014.  SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.. British journal of haematology. Abstract
Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey EH.  2009.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.. Blood. 113(1):28-36. Abstract